Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000

Core Viewpoint - Defence Therapeutics Inc. has successfully closed a private placement, raising approximately $9.6 million through the issuance of 17,445,455 units at a price of $0.55 per unit, which includes common shares and warrants [1][2]. Group 1: Private Placement Details - The private placement consists of 17,445,455 units, generating gross proceeds of $9,595,000.25 for the company [1]. - The company executed a binding term sheet with institutional investors for an additional $6 million as part of the private placement [2]. - Each unit includes one common share and one warrant, with warrants exercisable at $0.65 per share for 24 months [1][3]. Group 2: Use of Proceeds - The proceeds from the private placement will be utilized to advance the company's Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, develop partnerships, and for working capital [4]. Group 3: Warrant and Investor Details - A total of 10,909,091 warrants were issued, with an exercise price of $0.65 per share and a provision limiting ownership to 9.99% of outstanding shares [3]. - Investors received a corporate finance fee of 654,546 units and a non-refundable deposit of 118,182 units at the private placement price [3]. Group 4: Regulatory Compliance - All securities issued under this private placement are subject to resale restrictions in accordance with Canadian securities laws [5].